The announcement came a day after the World Health Organization backed the vaccine and as more than a dozen European countries have suspended the use of it amid concerns over the risk of blood clots.

John Nkengasong, director of the Africa Centers for Disease Control and Prevention, told a news conference that the “benefits still outweigh the risks” and that countries should “move forward” with the vaccination.

AstraZeneca said on Sunday a review of safety data of more than 17 million people vaccinated in the United Kingdom and European Union with its vaccine had shown no evidence of an increased risk of blood clots.

The head of the continent’s disease control body said that adverse reactions would be monitored and reported for future assessments on the vaccine.

Some African countries have already suspended use of the AstraZeneca vaccine.

On Friday the Democratic Republic of Congo delayed the rollout of the shot, citing the suspension of the use of the shots by European countries.

Many African states expect to receive AstraZeneca shots from the COVAX Facility, a global vaccine allocation plan co-led by the World Health Organization and partners including the Gavi vaccines alliance, which will be delivering vaccines for free to some low and lower-middle-income countries.

The European Medicines Agency is investigating reports of 30 cases of unusual blood disorders out of 5 million people who got the AstraZeneca vaccine in the EU. It said it has so far found no causal link. (Reporting by Giulia Paravicini; Editing by Nick Macfie)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]